Início › Câncer de Pulmão › Nevada
Ensaios clínicos de Câncer de Pulmão em Nevada
11 estudos para Câncer de Pulmão estão buscando participantes em locais em Nevada.
Cidades em Nevada
Texto oficial do estudo (Inglês)
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- OptumCare Cancer Care at Charleston, Las Vegas
- OptumCare Cancer Care at Fort Apache, Las Vegas
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT04267848Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Carson Tahoe Regional Medical Center, Carson City
- Comprehensive Cancer Centers of Nevada - Henderson, Henderson
- Comprehensive Cancer Centers of Nevada-Horizon Ridge, Henderson
- e mais 25
RecrutandoEstudo observacionalVoluntários saudáveis bem-vindos
Idades de 40 a 75 · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT05334069A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
- Renown Regional Medical Center-Renown Health Medical Oncology ( Site 0037), Reno
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT06312137Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
- Renown Regional Medical Center, Reno
RecrutandoFase 2/3
Idades 18 e acima · Todos os sexos · Atualizado em 22 de set. de 2026 · NCT07100080A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
- Cancer Care Specialists, Reno
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 8 de set. de 2026 · NCT06793215A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- Comprehensive Cancer Centers of Nevada, Las Vegas
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 8 de set. de 2026 · NCT06119581Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
- Renown Regional Medical Center, Reno
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 17 de ago. de 2026 · NCT05624996Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
- OptumCare Cancer Care at Charleston, Las Vegas
- OptumCare Cancer Care at Fort Apache, Las Vegas
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 3 de jun. de 2026 · NCT05642572Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
- OptumCare Cancer Care at Charleston, Las Vegas
- OptumCare Cancer Care at Fort Apache, Las Vegas
RecrutandoFase 2
18 Minutes · Todos os sexos · Atualizado em 5 de mai. de 2026 · NCT06031688LOTUS-CC: An Observational Research Study to Uncover Subtypes of Cancer Cachexia
- Carson Tahoe Regional Medical Center, Carson City
- Comprehensive Cancer Centers of Nevada - Henderson, Henderson
- OptumCare Cancer Care at Seven Hills, Henderson
- e mais 13
RecrutandoEstudo observacional
Idades 18 e acima · Todos os sexos · Atualizado em 9 de jan. de 2026 · NCT06073431Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening
- Renown Regional Medical Center, Reno
RecrutandoEstudo observacional
Idades 50 e acima · Todos os sexos · Atualizado em 5 de ago. de 2025 · NCT06122077Fonte: ClinicalTrials.gov, dados obtidos em 5 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.